Loading…
Lobbying Spend
—
Filings
25
Firms Hired
2
Active Period
2018–2023
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Ensuring Patient Access to Critical Breakthrough Products Act of 2019
2020 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5333
Prescription Digital Therapeutics to Support Recovery Act
2020 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: S. 3532
Ensuring Patient Access to Critical Breakthrough Products Act of 2019
2020 · third_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5333
Prescription Digital Therapeutics to Support Recovery Act
2020 · third_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: S. 3532
Ensuring Patient Access to Critical Breakthrough Products Act of 2019
2020 · second_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5333
Prescription Digital Therapeutics to Support Recovery Act
2020 · second_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: S. 3532
Ensuring Patient Access to Critical Breakthrough Products Act of 2019
2020 · first_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 5333
Prescription Digital Therapeutics to Support Recovery Act
2020 · first_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage. S. 3532, Prescription Digital Therapeutics to Support Recovery Act, as it relates to Medicare coverage.
Client expense: — · Firm income: $40,000
Matched citations: S. 3532
Ensuring Patient Access to Critical Breakthrough Products Act of 2019
2019 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
H.R. 5333, Ensuring Patient Access to Critical Breakthrough Products Act of 2019, as it relates to Medicare coverage.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5333
Source: Senate LDA